Breadcrumb

MEDIA_REFRESH_DATA

Media

U.S. News Room

Daiichi Sankyo Europe's Statement Regarding Esperion Therapeutics' Complaint
Download PDF

Industry Veteran, Dr. Mark Rutstein, Joins Daiichi Sankyo to Lead Global Oncology Clinical Development Program
Read More

Daiichi Sankyo, Inc. has taken measures to contribute to the overall effort to limit the spread of the virus that causes COVID-19.
Read More



Corporate Brochure
View Resource

Candidate Brochure
Download PDF


Rutgers 2025 Fellowship Brochure
Download PDF


These Daiichi Sankyo images are intended for news media use only.

Office building located at 211 Mt. Airy Road, Basking Ridge, NJ

Locations

A group of four Daiichi Sankyo corporate management member in suites

People

Collection of white tablets and blue, green and gray capsules

Medicines

Corporate Video


Locations

Office building located at 211 Mt. Airy Road, Basking Ridge, NJ

Daiichi Sankyo, Inc.
(Basking Ridge, NJ)

High resolution image
Low resolution image

Multi story office building in Tokyo

Daiichi Sankyo Co., Ltd.
(Tokyo, Japan)

High resolution image
Low resolution image

Multi story office building in Munich

Daiichi Sankyo Europe GmbH (Munich, Germany)

High resolution image
Low resolution image


 

People

White male in business suit

Ken Keller

Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc. and Global Head of the Daiichi Sankyo Oncology Business

Bio

High resolution image

Japanese man in business attire

Ken Takeshita, MD

Global Head, Research & Development

Bio

High resolution image

White male in business suit

Daniel Switzer

Head of U.S. Oncology Business Division

Bio

High resolution image


Medicines

Enhertu Product Logo

(fam-trastuzumab deruxtecan-nxki)

Savaysa Product Logo

(edoxaban) tablets

Turalio Product Logo

(pexidartinib)

See full prescribing information, including boxed warning regarding liver toxicity and medication guide.


Resources to Help You Get Answers

Investor Relations:

DaiichiSankyoIR@daiichisankyo.co.jp
Or please click here to be redirected to our global IR site

 

Media Relations:

Oncology & RD Pipeline:

Jennifer Brennan
Office 908-992-6631
Mobile 908-900-3183
jbrennan2@dsi.com

 

Iron Deficiency Anemia (U.S.):

Matt Coppola
Office 908-992-7102
mcoppola@dsi.com

 

Corporate Communications (U.S.):

Kim Wix
Office 908-992-6633
Mobile 908-656-5447
kwix@dsi.com

 

You may also send an email to our general U.S. Public Affairs/Corporate Communications mailbox here: CorporateCommunications@dsi.com

To reach our communications team for Europe, please email: press@daiichi-sankyo.eu

To reach our communications team in Tokyo, please visit: https://www.daiichisankyo.com/media/

To reach Investor Relations, please email: DaiichiSankyoIR@daiichisankyo.co.jp